Black Diamond Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
BDTX$1.60-14.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $59,350 | $64,437 |
| General and administrative | 27,110 | 28,391 |
| Total operating expenses | 86,460 | 92,828 |
| Loss from operations | (86,460) | (92,828) |
| Other income (expense): | ||
| Interest income | 1,924 | 2,031 |
| Other income (expense) | 2,094 | (354) |
| Gain on sale of IP | — | 2,232 |
| Total other income (expense), net | 4,018 | 3,909 |
| Equity in (losses) of unconsolidated entities | — | (2,250) |
| Net loss | $(82,442) | $(91,169) |
| Net loss per share, basic and diluted | $(1.88) | $(2.52) |
| Weighted average common shares outstanding, basic and diluted | 43,954,649 | 36,325,586 |
| Comprehensive loss: | ||
| Net loss | $(82,442) | $(91,169) |
| Other comprehensive (loss) income: | ||
| Change in unrealized (loss) gain on investments, net | 1,797 | (1,410) |
| Comprehensive loss | $(80,645) | $(92,579) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.